Cargando…

Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer

OBJECTIVE: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yetişir, Abdullah Evren, Paydaş, Semra, Büyükşimşek, Mahmut, Oğul, Ali, Yaprak, Özge, Zorludemir, Suzan, Ergin, Melek, Kolsuz, İrem, Kidi, Mehmet Mutlu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Médica Brasileira 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937598/
https://www.ncbi.nlm.nih.gov/pubmed/36820722
http://dx.doi.org/10.1590/1806-9282.20221123
_version_ 1784890457300402176
author Yetişir, Abdullah Evren
Paydaş, Semra
Büyükşimşek, Mahmut
Oğul, Ali
Yaprak, Özge
Zorludemir, Suzan
Ergin, Melek
Kolsuz, İrem
Kidi, Mehmet Mutlu
author_facet Yetişir, Abdullah Evren
Paydaş, Semra
Büyükşimşek, Mahmut
Oğul, Ali
Yaprak, Özge
Zorludemir, Suzan
Ergin, Melek
Kolsuz, İrem
Kidi, Mehmet Mutlu
author_sort Yetişir, Abdullah Evren
collection PubMed
description OBJECTIVE: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the relationship of enhancer of zeste homolog 2 and mucin 1 expressions with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. METHODS: A total of 151 patients were included in the study. Enhancer of zeste homolog 2 and mucin 1 expressions were evaluated in the biopsy materials pre-neoadjuvant chemotherapy and post-neoadjuvant chemotherapy surgical material, and their relationship with pathological complete response was investigated. RESULTS: The pathological complete response rates were significantly higher among the hormone receptor-negative patients, those with a high Ki-67 score, and patients with HER2-positive. Higher pathological complete response rates were obtained from patients with enhancer of zeste homolog 2 expression positivity pre-neoadjuvant chemotherapy. In addition, after neoadjuvant chemotherapy, enhancer of zeste homolog 2 expression was found to be completely negative in materials with pathological complete response; that is, in breast tissues considered to be tumor-free. While there was no significant relationship between mucin 1 expression and pathological complete response pre-neoadjuvant chemotherapy, mucin 1 expression was determined to significantly differ between the tissues with and without pathological complete response among the surgical materials examined. CONCLUSION: In our study investigating the relationship between enhancer of zeste homolog 2 and mucin 1 expression and pathological complete response in patients who received neoadjuvant chemotherapy, we found that enhancer of zeste homolog 2 expression could be used as a predictive marker for pathological complete response. However, mucin 1 expression was not associated with pathological complete response.
format Online
Article
Text
id pubmed-9937598
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Associação Médica Brasileira
record_format MEDLINE/PubMed
spelling pubmed-99375982023-02-18 Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer Yetişir, Abdullah Evren Paydaş, Semra Büyükşimşek, Mahmut Oğul, Ali Yaprak, Özge Zorludemir, Suzan Ergin, Melek Kolsuz, İrem Kidi, Mehmet Mutlu Rev Assoc Med Bras (1992) Original Article OBJECTIVE: Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the relationship of enhancer of zeste homolog 2 and mucin 1 expressions with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. METHODS: A total of 151 patients were included in the study. Enhancer of zeste homolog 2 and mucin 1 expressions were evaluated in the biopsy materials pre-neoadjuvant chemotherapy and post-neoadjuvant chemotherapy surgical material, and their relationship with pathological complete response was investigated. RESULTS: The pathological complete response rates were significantly higher among the hormone receptor-negative patients, those with a high Ki-67 score, and patients with HER2-positive. Higher pathological complete response rates were obtained from patients with enhancer of zeste homolog 2 expression positivity pre-neoadjuvant chemotherapy. In addition, after neoadjuvant chemotherapy, enhancer of zeste homolog 2 expression was found to be completely negative in materials with pathological complete response; that is, in breast tissues considered to be tumor-free. While there was no significant relationship between mucin 1 expression and pathological complete response pre-neoadjuvant chemotherapy, mucin 1 expression was determined to significantly differ between the tissues with and without pathological complete response among the surgical materials examined. CONCLUSION: In our study investigating the relationship between enhancer of zeste homolog 2 and mucin 1 expression and pathological complete response in patients who received neoadjuvant chemotherapy, we found that enhancer of zeste homolog 2 expression could be used as a predictive marker for pathological complete response. However, mucin 1 expression was not associated with pathological complete response. Associação Médica Brasileira 2023-02-17 /pmc/articles/PMC9937598/ /pubmed/36820722 http://dx.doi.org/10.1590/1806-9282.20221123 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Yetişir, Abdullah Evren
Paydaş, Semra
Büyükşimşek, Mahmut
Oğul, Ali
Yaprak, Özge
Zorludemir, Suzan
Ergin, Melek
Kolsuz, İrem
Kidi, Mehmet Mutlu
Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
title Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
title_full Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
title_fullStr Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
title_full_unstemmed Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
title_short Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
title_sort effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937598/
https://www.ncbi.nlm.nih.gov/pubmed/36820722
http://dx.doi.org/10.1590/1806-9282.20221123
work_keys_str_mv AT yetisirabdullahevren effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer
AT paydassemra effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer
AT buyuksimsekmahmut effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer
AT ogulali effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer
AT yaprakozge effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer
AT zorludemirsuzan effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer
AT erginmelek effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer
AT kolsuzirem effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer
AT kidimehmetmutlu effectsofenhancerofzestehomolog2andmucin1expressionsontreatmentresponseinbreastcancer